Immunoglobulin Light-chain Amyloidosis
"Immunoglobulin Light-chain Amyloidosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.
Descriptor ID |
D000075363
|
MeSH Number(s) |
C04.557.595.250 C18.452.845.500.550 C20.683.515.507 C20.683.780.565
|
Concept/Terms |
Immunoglobulin Light-chain Amyloidosis- Immunoglobulin Light-chain Amyloidosis
- Immunoglobulin Light chain Amyloidosis
- Immunoglobulin Light-chain Amyloidoses
- Amyloidosis, Primary
- AL Amyloidosis
- AL Amyloidoses
- Primary Systemic Amyloidosis
- Amyloidoses, Primary Systemic
- Amyloidosis, Primary Systemic
- Primary Systemic Amyloidoses
- Systemic Amyloidoses, Primary
- Systemic Amyloidosis, Primary
- Amyloidosis, Immunoglobulin Light-chain
- Amyloidosis, Immunoglobulin Light chain
- Primary Amyloidosis
- Amyloidoses, Primary
- Primary Amyloidoses
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Light-chain Amyloidosis".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Light-chain Amyloidosis".
This graph shows the total number of publications written about "Immunoglobulin Light-chain Amyloidosis" by people in this website by year, and whether "Immunoglobulin Light-chain Amyloidosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin Light-chain Amyloidosis" by people in Profiles.
-
Anand SK, Staron A, Mendelson LM, Joshi T, Burke N, Sanchorawala V, Verma A. Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease. Am J Hematol. 2024 Nov; 99(11):2140-2151.
-
Anand SK, Sanchorawala V, Verma A. Systemic Amyloidosis and Kidney Transplantation: An Update. Semin Nephrol. 2024 Jan; 44(1):151496.
-
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 02; 57(2):295-298.
-
Arnall JR, Usmani SZ, Adamu H, Mishkin J, Bhutani M. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement. J Oncol Pharm Pract. 2019 Jun; 25(4):1021-1025.
-
Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011 Dec 15; 118(25):6610-7.